Canadian application, no grantCanada
Method for treating huntington's disease using glial cell line-derived neurotrophic factor (gdnf) protein product
CA 2220914 A1 · Owner: Amgen Inc. · Inventors: Martin, David; Miller, Gerald D.
Overview
Drawings and full text
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Methods are provided for preventing or reducing N-methyl-D-aspartate (NMDA) receptor agonist-mediated neuronal cell death by administering a glial cell line-derived neurotrophic factor (GDNF) protein product.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 18, 1997. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended March 18, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 18, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledMarch 18, 1997
GrantedNo grant recorded
Term endedMarch 18, 2017
Patent numberCA 2220914 A1
Classification (IPC)A61K38/18 +2 more
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.